Delivery Order SPE2DB22D1202-SPE2DB25FVME0
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,041.38 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract utilized competitive procurement procedures with no...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in treating inflammatory conditions. The contract was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $28,014.24 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside, competitively awarded contract. The work is performed at AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and was competitively awarded without set-aside designation. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $7,810.81 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The contract, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $54,808.47 firm fixed-price delivery order for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This delivery order, issued on August 26, 2025, represents performance through August 27, 2025, and will be fulfilled at the contractor's location in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, awarded on April 21, 2025, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by April 22, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVME0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $51,847.31 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support platform enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs and other federal health systems worldwide. The IDC demonstrates AmerisourceBergen's established capability as a critical pharmaceutical distributor for federal medical procurement, with a track record of fulfilling diverse medical supply requirements through competitively awarded delivery orders across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $51.8k | 9/23/25 |